Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Branford

Showing results (21-30 of 136) with videos related to

Pageof 14
Sort By:
Haematologica|December 1, 2022
Measurable residual disease in chronic myeloid leukemiaSusan Branford, Jane F Apperley
Leukemia & Lymphoma|May 27, 2011
Minimal residual disease: the advantages of digital over analog polymerase chain reactionDavid M Ross, Susan Branford
Seminars in Hematology|September 30, 2010
Practical considerations for monitoring patients with chronic myeloid leukemiaSusan Branford, Timothy P Hughes
Clinical Lymphoma & Myeloma|September 26, 2009
Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reactionTimothy P Hughes, Susan Branford
Therapeutic Advances in Hematology|October 4, 2016
Current developments in molecular monitoring in chronic myeloid leukemiaJustine Ellen Marum, Susan Branford
Cancers|February 15, 2022
Genomic Mechanisms Influencing Outcome in Chronic Myeloid LeukemiaAdelina Fernandes, Naranie Shanmuganathan, Susan Branford
Current Hematologic Malignancy Reports|August 6, 2022
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and PrognosticationNur Hezrin Shahrin, Carol Wadham, Susan Branford
British Journal of Haematology|June 13, 2002
Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneSusan Branford, Timothy P Hughes, Zbigniew Rudzki
Blood|November 3, 2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Susan Branford, Junia V Melo, Timothy P Hughes
Pathology|September 2, 2011
Molecular methods in diagnosis and monitoring of haematological malignanciesDavid T Yeung, Wendy T Parker, Susan Branford
Pageof 14

Showing results (21-30 of 136) with videos related to

Sort By:
Pageof 14
Haematologica|December 1, 2022
Measurable residual disease in chronic myeloid leukemiaSusan Branford, Jane F Apperley
Leukemia & Lymphoma|May 27, 2011
Minimal residual disease: the advantages of digital over analog polymerase chain reactionDavid M Ross, Susan Branford
Seminars in Hematology|September 30, 2010
Practical considerations for monitoring patients with chronic myeloid leukemiaSusan Branford, Timothy P Hughes
Clinical Lymphoma & Myeloma|September 26, 2009
Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reactionTimothy P Hughes, Susan Branford
Therapeutic Advances in Hematology|October 4, 2016
Current developments in molecular monitoring in chronic myeloid leukemiaJustine Ellen Marum, Susan Branford
Cancers|February 15, 2022
Genomic Mechanisms Influencing Outcome in Chronic Myeloid LeukemiaAdelina Fernandes, Naranie Shanmuganathan, Susan Branford
Current Hematologic Malignancy Reports|August 6, 2022
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and PrognosticationNur Hezrin Shahrin, Carol Wadham, Susan Branford
British Journal of Haematology|June 13, 2002
Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneSusan Branford, Timothy P Hughes, Zbigniew Rudzki
Blood|November 3, 2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Susan Branford, Junia V Melo, Timothy P Hughes
Pathology|September 2, 2011
Molecular methods in diagnosis and monitoring of haematological malignanciesDavid T Yeung, Wendy T Parker, Susan Branford
Pageof 14